Ionis Pharmaceuticals, Inc. (IONS)
Nasdaq: IONS · Pharmaceutical Preparations · Carlsbad, CA · filing with the SEC since 1996
Who owns Ionis Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
3
Capital World Investors holds 12.8% of Common Stock, as its SCHEDULE 13G/A filed May 14, 2026 says.
Directors and officers
23
report now, of 29 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Capital World Investors
SCHEDULE 13G/A · filed May 14, 2026 · Common Stock · 11.1% in Jan 7, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 12, 2025 · Common Stock · reported falling below 5%
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed May 15, 2026 · COMMON STOCK · reported falling below 5%, from 5.6% in Feb 17, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 10.4% in Jan 8, 2025
What IONS reports owning in othersstakes of 5% or more, and other ties
4 subsidiaries in 1 country, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
126sales
2purchases
98sales on a scheduled plan
19people selling
$134Msold, in dollars
$1.1Mbought, in dollars
Open-market trades on Form 4 from Oct 19, 2025 to Oct 19, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 19, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window20 of 29 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Monia Brett P | Chief Executive Officer | 13 | $30.3M | 11 | 0 | $0 |
| Hougen Elizabeth L | EVP, Finance & CFO | 5 | $17.9M | 3 | 0 | $0 |
| Bennett C Frank | EVP, Chief Scientific Officer | 10 | $16.7M | 8 | 0 | $0 |
| Geary Richard S | EVP, Chief Development Officer | 11 | $9.6M | 11 | 0 | $0 |
| Devers Shannon L. | EVP, Chief Human Resources Ofc | 13 | $8.2M | 11 | 0 | $0 |
| Loscalzo Joseph | director | 5 | $7.1M | 5 | 0 | $0 |
| Klein Joseph III | director | 12 | $6.0M | 12 | 0 | $0 |
| Swayze Eric | EVP Research | 9 | $5.2M | 5 | 0 | $0 |
| Diaz Allene M. | director | 4 | $5.2M | 4 | 0 | $0 |
| Kordasiewicz Holly B. | EVP, Chief Development Officer | 4 | $4.8M | 3 | 0 | $0 |
| Wender Joseph H | director | 6 | $4.3M | 6 | 0 | $0 |
| Schneider Eugene | EVP, Chf Clinical Develop Ofcr | 4 | $3.7M | 2 | 0 | $0 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | 4 | $3.3M | 2 | 0 | $0 |
| Herman Joan E | director | 2 | $3.2M | 0 | 0 | $0 |
| Baroldi Joseph | EVP, Chief Business Officer | 11 | $2.6M | 7 | 0 | $0 |
| O'Neil Patrick R. | EVP CLO & General Counsel | 4 | $2.2M | 2 | 0 | $0 |
| Birchler Brian | EVP, Corp and Development Ops | 4 | $1.8M | 1 | 0 | $0 |
| Berthelsen Spencer R | director | 2 | $1.2M | 2 | 0 | $0 |
| Parshall B Lynne | COO | 3 | $800,000 | 3 | 0 | $0 |
| Hayden Michael R | director | 0 | $0 | 0 | 2 | $1.1M |